Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Duke experience of belantamb mafodotin shows ORR of 67%, median PFS 9.5 months, median OS NR at 3-years, cycle delay in 28 (93%) with 85% due to ocular AEs (2% grade ≥3), treatment discontinuation from ocular tox in 4 (13%).”
Title: Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis
Authors: Mihir N. Patel, Susan C. Locke, Caroline Falvey, Jesse D. Troy, Kris W. Herring, Amanda Bolgioni-Smith, Cherie Elcock, Laura Iadeluca, Cristiana Costa Chase, Cristina Gasparetto, Mark S. Newman, Thomas W. LeBlanc
Read the Full Article in Clinical Lymphoma, Myeloma and Leukemia.
More posts featuring Robert Orlowski.
